Next-generation characterization of the Cancer Cell Line Encyclopedia.
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
02
06
2018
accepted:
09
04
2019
pubmed:
10
5
2019
medline:
7
2
2020
entrez:
10
5
2019
Statut:
ppublish
Résumé
Large panels of comprehensively characterized human cancer models, including the Cancer Cell Line Encyclopedia (CCLE), have provided a rigorous framework with which to study genetic variants, candidate targets, and small-molecule and biological therapeutics and to identify new marker-driven cancer dependencies. To improve our understanding of the molecular features that contribute to cancer phenotypes, including drug responses, here we have expanded the characterizations of cancer cell lines to include genetic, RNA splicing, DNA methylation, histone H3 modification, microRNA expression and reverse-phase protein array data for 1,072 cell lines from individuals of various lineages and ethnicities. Integration of these data with functional characterizations such as drug-sensitivity, short hairpin RNA knockdown and CRISPR-Cas9 knockout data reveals potential targets for cancer drugs and associated biomarkers. Together, this dataset and an accompanying public data portal provide a resource for the acceleration of cancer research using model cancer cell lines.
Identifiants
pubmed: 31068700
doi: 10.1038/s41586-019-1186-3
pii: 10.1038/s41586-019-1186-3
pmc: PMC6697103
mid: NIHMS1032762
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Histones
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-508Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180922
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210950
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA025720
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA176058
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224068
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211461
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219943
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA098258
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217842
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210949
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA225191
Pays : United States
Références
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
doi: 10.1038/nature11003
Li, H. et al. The landscape of cancer cell line metabolism. Nat. Med. https://doi.org/10.1038/s41591-019-0404-8 (2019).
Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).
doi: 10.1016/j.cell.2016.06.017
Ben-David, U. et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 560, 325–330 (2018).
doi: 10.1038/s41586-018-0409-3
Tsherniak, A. et al. Defining a cancer dependency Map. Cell 170, 564–576 (2017).
doi: 10.1016/j.cell.2017.06.010
McDonald, E. R. III et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592 (2017).
doi: 10.1016/j.cell.2017.07.005
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
doi: 10.1038/ng.3984
Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013).
doi: 10.1126/science.1229259
Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298–1303 (2011).
doi: 10.1038/nm.2430
Marra, G. et al. Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc. Natl Acad. Sci. USA 95, 8568–8573 (1998).
doi: 10.1073/pnas.95.15.8568
Esakova, O. & Krasilnikov, A. S. Of proteins and RNA: the RNase P/MRP family. RNA 16, 1725–1747 (2010).
doi: 10.1261/rna.2214510
Hands-Taylor, K. L. et al. Heterodimerization of the human RNase P/MRP subunits Rpp20 and Rpp25 is a prerequisite for interaction with the P3 arm of RNase MRP RNA. Nucleic Acids Res. 38, 4052–4066 (2010).
doi: 10.1093/nar/gkq141
Doherty, J. R. & Cleveland, J. L. Targeting lactate metabolism for cancer therapeutics. J. Clin. Invest. 123, 3685–3692 (2013).
doi: 10.1172/JCI69741
Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994).
doi: 10.1073/pnas.91.21.9700
Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386–1391 (2013).
doi: 10.1038/ng.2777
Creech, A. L. et al. Building the Connectivity Map of epigenetics: chromatin profiling by quantitative targeted mass spectrometry. Methods 72, 57–64 (2015).
doi: 10.1016/j.ymeth.2014.10.033
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A. & Skotheim, R. I. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 35, 2413–2427 (2016).
doi: 10.1038/onc.2015.318
Dewaele, M. et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J. Clin. Invest. 126, 68–84 (2016).
doi: 10.1172/JCI82534
Rallapalli, R., Strachan, G., Cho, B., Mercer, W. E. & Hall, D. J. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J. Biol. Chem. 274, 8299–8308 (1999).
doi: 10.1074/jbc.274.12.8299
Gembarska, A. et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat. Med. 18, 1239–1247 (2012).
doi: 10.1038/nm.2863
Boutz, P. L., Bhutkar, A. & Sharp, P. A. Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev. 29, 63–80 (2015).
doi: 10.1101/gad.247361.114
Maruvka, Y. E. et al. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat. Biotechnol. 35, 951–959 (2017).
doi: 10.1038/nbt.3966
Zhang, Y. et al. Ribosomal proteins Rpl22 and Rpl22l1 control morphogenesis by regulating pre-mRNA splicing. Cell Reports 18, 545–556 (2017).
doi: 10.1016/j.celrep.2016.12.034
Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005).
doi: 10.1038/nature03702
Li, J. et al. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31, 225–239 (2017).
doi: 10.1016/j.ccell.2017.01.005
Chen, Y. N. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 535, 148–152 (2016).
doi: 10.1038/nature18621
Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature 543, 733–737 (2017).
doi: 10.1038/nature21702
Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389–393 (2013).
doi: 10.1038/nature12831
The Cancer Cell Line Encyclopedia Consortium & The Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line datasets. Nature 528, 84–87 (2015).
doi: 10.1038/nature15736
Haverty, P. M. et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333–337 (2016).
doi: 10.1038/nature17987
Geeleher, P., Gamazon, E. R., Seoighe, C., Cox, N. J. & Huang, R. S. Consistency in large pharmacogenomic studies. Nature 540, E1–E2 (2016).
doi: 10.1038/nature19838
Bouhaddou, M. et al. Drug response consistency in CCLE and CGP. Nature 540, E9–E10 (2016).
doi: 10.1038/nature20580
Mpindi, J. P. et al. Consistency in drug response profiling. Nature 540, E5–E6 (2016).
doi: 10.1038/nature20171
Yu, C. et al. High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. Nat. Biotechnol. 34, 419–423 (2016).
doi: 10.1038/nbt.3460
King, A. J. et al. Abstract 2116: Combining the power of different profiling approaches to better understand the activity of kinase inhibitor drugs. Cancer Res. 77, 2116–2116 (2017).
Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
doi: 10.1186/gb-2011-12-1-r1
Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138–142 (2013).
doi: 10.1038/nature12688
Boyle, P. et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. 13, R92 (2012).
doi: 10.1186/gb-2012-13-10-r92
Brat, D. J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481–2498 (2015).
doi: 10.1056/NEJMoa1402121
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).
doi: 10.1016/j.cell.2014.09.050
Huang, F. W. et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis 4, e176 (2015).
doi: 10.1038/oncsis.2015.39
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
doi: 10.1038/nbt.2514
Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016).
doi: 10.1038/nature19057
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.11–11.10.33 (2013).
Wala, J. A. et al. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 28, 581–591 (2018).
doi: 10.1101/gr.221028.117
Haas, B. et al. STAR-Fusion: fast and accurate fusion transcript detection from RNA-seq. Preprint at https://www.bioRxiv.org/content/10.1101/120295v1 (2017).
Kasar, S. et al. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866 (2015).
doi: 10.1038/ncomms9866
Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
doi: 10.1038/ng.3557
The Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950–965 (2017).
doi: 10.1016/j.cell.2017.10.014
Haradhvala, N. J. et al. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat. Commun. 9, 1746 (2018).
doi: 10.1038/s41467-018-04002-4
Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
doi: 10.1038/nbt.2203
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
doi: 10.1093/bioinformatics/btr167
Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
doi: 10.1186/gb-2012-13-10-r87
Ziller, M. J. et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477–481 (2013).
doi: 10.1038/nature12433
van der Maaten, L. & Hinton, G. Visualizing high-dimensional data using t-SNE. J. Mach. Learn. Res. 9, 2579–2605 (2008).
Szklarczyk, D. et al. STRINGv10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447–D452 (2015).
doi: 10.1093/nar/gku1003
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
doi: 10.1158/2159-8290.CD-12-0095
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
doi: 10.1126/scisignal.2004088
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530–1532 (2012).
doi: 10.1093/bioinformatics/bts196
GTEx Consortium. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
doi: 10.1038/nature24277
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
doi: 10.1093/nar/gkv007
Smyth, G. K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, 1–25 (2004).
Akbani, R. et al. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat. Commun. 5, 3887 (2014).
doi: 10.1038/ncomms4887
Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1–22 (2010).
doi: 10.18637/jss.v033.i01